IRVINE, Calif. - Axonics, Inc. (NASDAQ: AXNX), a medical technology company, announced today that its shareholders have approved a merger agreement with Boston Scientific Corporation (NYSE: NYSE:BSX). The approval came during a special meeting where a majority of the outstanding shares entitled to vote supported the merger.
Raymond W. Cohen, CEO of Axonics, expressed gratitude towards the shareholders for their strong support and emphasized the potential global impact of combining forces with Boston Scientific. He highlighted the opportunity to expand the reach of their life-changing therapies to more patients.
The transaction is anticipated to close in the first half of 2024, subject to certain conditions, including antitrust approvals and clearances in the U.S. and other jurisdictions.
Axonics specializes in developing and commercializing innovative products for adults with bladder and bowel dysfunction. Their sacral neuromodulation systems and urethral bulking hydrogel Bulkamid® are designed to provide effective and safe treatment options.
The company has been recognized for its rapid growth, ranking second in the 2023 Financial Times list of the fastest-growing companies in the Americas.
The merger is expected to enhance the combined entity's ability to serve a larger patient base. In the U.S. alone, moderate to severe urinary incontinence affects an estimated 28 million women, and fecal incontinence impacts around 19 million adults.
The press release also includes a cautionary statement highlighting that forward-looking statements involve risks and uncertainties. These include the risk of delays or failure to complete the merger, potential integration challenges, and the impact of the merger announcement on Axonics' business and operations.
This news article is based on a press release statement and does not include any assumptions or speculative content. It focuses on the factual reporting of the shareholder approval for the merger between Axonics and Boston Scientific.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.